Toxic Megacolon – A Three Case Presentation

1. Cohen SH, Gerding DN, Johnson S, et al. Clinical Practice Guidelines for Clostridium difficile infection in adults: Update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infection Control and Hospital Epidemiology. 2010;31:431-455.10.1086/65170620307191Search in Google Scholar

2. Sartelli M, Malangoni MA, Abu-Zidan FM, et al. WSES guidelines for management of Clostridium difficile infection in surgical patients. World J Emerg Surg. 2015;10:38.10.1186/s13017-015-0033-6454587226300956Search in Google Scholar

3. Dallal RM, Harbrecht BG, Boujoukas AJ, et al. Fulminant Clostridium difficile: an underappreciated and increasing cause of death and complications. Ann Surg. 2002;235:363–7210.1097/00000658-200203000-00008142244211882758Search in Google Scholar

4. Adams SD, Mercer DW. Fulminant Clostridium difficile colitis. Curr Opin Crit Care. 2007;13:450–5.10.1097/MCC.0b013e328263887917599017Search in Google Scholar

5. Rubin MS, Bodenstein LE, Kent KC. Severe Clostridium difficile colitis. Dis Colon Rectum. 1995;38(4):350.10.1007/BF020542207720439Search in Google Scholar

6. Koo HL, Koo DC, Musher DM, DuPont HL. Antimotility Agents for the Treatment of Clostridium difficile diarrhea and colitis. Oxford Journals Medicine & Health Clinical Infectious Diseases. 2009; 48(5):598-605.10.1086/59671119191646Search in Google Scholar

7. Sayedy L, Kothari D, Richards RJ. Toxic megacolon associated Clostridium difficile colitis. World J Gastrointest Endoc. 2010;2(8):293-7.10.4253/wjge.v2.i8.293299914921160629Search in Google Scholar

8. Grigorescu BL, Fodor RS, Cioc AD, et al. Factors Favouring the Development of Clostridium Difficile Infection in Critically Ill Patients. The Journal of Critical Care Medicine. 2016;2(1):38-43.10.1515/jccm-2016-0006593914129967835Search in Google Scholar

9. Martin JS, Monaghan TM, Wilcox MH. Clostridium difficile infection: epidemiology, diagnosis and understanding transmission. Nat Rev Gastroenterol Hepatol. 2016;13(4):206-16.10.1038/nrgastro.2016.2526956066Search in Google Scholar

10. Sayedy L, Kothari D, Richards RJ. Toxic megacolon associated Clostridium difficile colitis. World J Gastrointest Endosc. 2010;2(8):293–297.10.4253/wjge.v2.i8.293Search in Google Scholar

11. Stallmach A. Clostridium difficile infection: What is currently available for treatment? Internist (Berl). 2016;57(12):1182-1190.10.1007/s00108-016-0149-027796474Search in Google Scholar

10. Abou Chakra CN, McGeer A, Labbé AC, et al. Factors Associated With Complications of Clostridium difficile Infection in a Multicenter Prospective Cohort. Clin Infect Dis. 2015;61(12):1781-8.10.1093/cid/civ749465753826338788Search in Google Scholar

11. Shivashankar R, Khanna S, Kammer PP, et al. Clinical factors associated with development of severe-complicated Clostridium difficile infection. Clin Gastroenterol Hepatol. 2013;11(11):1466-71.10.1016/j.cgh.2013.04.050384676823702192Search in Google Scholar

12. Khanafer N, Barbut F, Eckert C, et al. Factors predictive of severe Clostridium difficile infection depend on the definition used. Anaerobe.2016;37:43-8.10.1016/j.anaerobe.2015.08.00226335160Search in Google Scholar

13. Mulki R, Baumann AJ, Alnabelsi T, et al. Body mass index greater than 35 is associated with severe Clostridium difficile infection. Aliment Pharmacol Ther. 2016 Oct 28. doi: 10.1111/apt.13832. [Epub ahead of print]10.1111/apt.1383227790736Search in Google Scholar

14. Lu H, Wu Z, Xu W, Yang J, Chen Y, Li L. Intestinal microbiota was assessed in cirrhotic patients with hepatitis B virus infection. Intestinal microbiota of HBV cirrhotic patients. Microb Ecol. 2011;61(3):693-703.10.1007/s00248-010-9801-821286703Search in Google Scholar

15. Aly AM, Adel A, El-Gendy AO, Essam TM, Aziz RK. Gut microbiome alterations in patients with stage 4 hepatitis C.Gut Pathog. 2016;8(1):42.10.1186/s13099-016-0124-2502048027625705Search in Google Scholar

16. Naimushin A, Eliasaf S, Livneh A. Clostridium difficile-associated diarrhea: causes and relationship to reactive arthritis. Harefuah. 2011;150(1):64-6.Search in Google Scholar

17. Yu JH, Kim NY, Lee HM, et al. A case of pseudomembranous colitis in a juvenile rheumatoid arthritis patient taking methotrexate. Korean J Gastroenterol. 2010;56(6):387-90.10.4166/kjg.2010.56.6.38721173564Search in Google Scholar

18. Vaahtovuo J, Munukka E, Korkeamäki M, Luukkainen R, Toivanen P. Fecal microbiota in early rheumatoid arthritis. J Rheumatol. 2008;35(8):1500-5.Search in Google Scholar

19. Ofosu A. Clostridium difficile infection: a review of current and emerging therapies. Ann Gastroenterol. 2016;29(2):147-54.10.20524/aog.2016.0006480573327065726Search in Google Scholar

20. Arvand M, Hauri AM, Zaiss NH, Witte W, Bettge-Weller G. Clostridium difficile ribotypes 001, 017, and 027 are associated with lethal C. difficile infection in Hesse, Germany. Euro Surveill. 2009;14(45): pii: 19403.10.2807/ese.14.45.19403-en19941785Search in Google Scholar

21. Rao K, Micic D, Natarajan M, et al. Clostridium difficile ribotype 027: relationship to age, detectability of toxins A or B in stool with rapid testing, severe infection, and mortality. Clin Infect Dis. 2015;61(2):233-41.10.1093/cid/civ254456599325828993Search in Google Scholar

22. Dubberke ER, Sadhu J, Gatti R, et al. Severity of Clostridium difficile-associated disease (CDAD) in allogeneic stem cell transplant recipients: evaluation of a CDAD severity grading system. Infect Control Hosp Epidemiol. 2007;28:208–11.10.1086/51179217265405Search in Google Scholar

23. Henrich TJ, Krakower D, Bitton A, Yokoe DS. Clinical Risk Factors for Severe Clostridium difficile–associated Disease. Emerg Infect Dis. 2009;15(3):415–22.10.3201/eid1503.080312268110919239754Search in Google Scholar

24. Akamine CM, Ing MB, Jackson CS, Loo LK. The efficacy of intracolonic vancomycin for severe Clostridium difficile colitis: a case series. BMC Infect Dis. 2016;16:316.10.1186/s12879-016-1657-1493754127388627Search in Google Scholar

25. Britt NS, Steed ME, Potter EM, Clough LA. Tigecycline for the Treatment of Severe and Severe Complicated Clostridium difficile Infection. Infect Dis Ther. 2014;3(2):321–331.10.1007/s40121-014-0050-x426962225466443Search in Google Scholar

26. Gergely Szabo B, Kadar B, Szidonia Lenart K, et al. Use of intravenous tigecycline in patients with severe Clostridium difficile infection: a retrospective observational cohort study. Clin Microbiol Infect. 2016. doi: 10.1016/j.cmi.2016.08.017. [Epub ahead of print]10.1016/j.cmi.2016.08.01727599690Search in Google Scholar

27. Larson KC, Belliveau PP, Spooner LM. Tigecycline for the treatment of severe Clostridium difficile infection. Ann Pharmacother. 2011;45(7-8):1005-10.10.1345/aph.1Q08021730279Search in Google Scholar